Most patients with early active relapsing-remitting MS treated with ocrelizumab did not see worse hand function or ambulation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results